{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:11:04Z","timestamp":1789708264657,"version":"4.0.1"},"reference-count":43,"publisher":"Informa UK Limited","issue":"7","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2020,7,2]]},"DOI":"10.1080\/14712598.2020.1772747","type":"journal-article","created":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T05:49:53Z","timestamp":1590040193000},"page":"823-827","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":16,"title":["Will the US$5 million onasemnogene abeparvosec treatment for spinal muscular atrophy represent \u2018value for money\u2019 for the NHS? A rapid inquiry into suggestions that it may be cost-effective"],"prefix":"10.1080","volume":"20","author":[{"given":"Martin","family":"Connock","sequence":"first","affiliation":[{"name":"Warwick Medical School, Faculty of Science Engineering and Medicine, University of Warwick, Coventry, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lazaros","family":"Andronis","sequence":"additional","affiliation":[{"name":"Warwick Medical School, Faculty of Science Engineering and Medicine, University of Warwick, Coventry, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Auguste","sequence":"additional","affiliation":[{"name":"Warwick Medical School, Faculty of Science Engineering and Medicine, University of Warwick, Coventry, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1091-9139","authenticated-orcid":false,"given":"Claude","family":"Dussart","sequence":"additional","affiliation":[{"name":"School of Pharmacy (ISPB)\/EA P2S\/Pharmacy Department, University of Lyon, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Armoiry","sequence":"additional","affiliation":[{"name":"Warwick Medical School, Faculty of Science Engineering and Medicine, University of Warwick, Coventry, UK"},{"name":"School of Pharmacy (ISPB)\/UMR CNRS 5510 MATEIS\/Edouard Herriot Hospital, Pharmacy Department, University of Lyon, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2020,6,11]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hci128"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcm021"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462307071012"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462307051550"},{"key":"cit0005","unstructured":"UK-Gov. How UK orphan medicinal products will be managed in a no deal scenario; 2019 [cited 2020 May 29]. Available from: https:\/\/www.gov.uk\/guidance\/how-uk-orphan-medicinal-products-will-be-managed-in-a-no-deal-scenario"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.331.7523.1019"},{"key":"cit0007","unstructured":"Martin J. Expensive drugs for rare diseases. [cited 2020 May 29]. Available from: https:\/\/www.cadth.ca\/media\/symposium_pdfs\/cadth_symposium06_ppt_Martin2.pdf"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-8-180"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-019-01047-0"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0724-z"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24864"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0417-15.2015"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1177\/0883073807305788"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2017.11.005"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2017.11.004"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2016.11.043"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2016.11.039"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2019.1704732"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2017.1364159"},{"key":"cit0020","unstructured":"[cited 2020 May 29]. Available from: https:\/\/pharmaintelligence.informa.com\/resources\/product-content\/novartis-pharma-ceo-sees-zolgensma-supplanting-spinraza"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2019.1601484"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmrj.2016.07.243"},{"key":"cit0023","unstructured":"Cadth common drug review pharmacoeconomic report for nusinersen. 2018, p. 83."},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2017.4409"},{"key":"cit0025","unstructured":"NICE NIfHaCE. Nusinersen for treating spinal muscular atrophy.ID1069 committee papers. 2018. Available from: https:\/\/nice.org.uk\/guidance\/indevelopment\/gid-ta10281\/documents"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-019-00769-6"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0695-0"},{"key":"cit0028","unstructured":"OECD. [cited 2020 May 29]. Available from: https:\/\/www.oecd.org \u203a sdd \u203a prices-ppp"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-130-9-199905040-00003"},{"key":"cit0030","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198529446.001.0001","volume-title":"Methods for the economic evaluation of health care programmes","author":"Drummond MF","year":"2005","edition":"3"},{"key":"cit0031","volume-title":"Economic analysis in health care","author":"Morris S","year":"2012","edition":"2"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0671-8"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1177\/1536867X1801800114"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1177\/1536867X0400400302"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-019-00871-9"},{"issue":"3","key":"cit0036","first-page":"349","volume":"32","author":"Elek P","year":"2017","journal-title":"Health Policy Plan"},{"key":"cit0037","unstructured":"Kanavos P, Fontrier A, Gill J, et al. The impact of external reference pricing within and across countries 2017 [cited]. London School of Economics, London."},{"key":"cit0038","unstructured":"Rare-disease-commissioning-group. [cited 2020 May 29]. Available from: https:\/\/www.england.nhs.uk\/commissioning\/wp-content\/uploads\/sites\/12\/2016\/09\/rdag-tor-aug-16.pdf"},{"key":"cit0039","unstructured":"House-of-Commons. Hansard ministerial statements for 08 october: written ministerial statements; health; paroxysmal nocturnal haemoglobinuria. 2008 Oct 8 [cited 2020 May 29]. Available from: https:\/\/publications.parliament.uk\/pa\/cm200708\/cmhansrd\/cm081008\/wmstext\/81008m0001.htm"},{"key":"cit0040","unstructured":"Griffiths R. 2009 [cited 2020 May 29]. Available from: https:\/\/publications.parliament.uk\/pa\/cm200809\/cmselect\/cmhealth\/1020\/1020w207.htm"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.3402\/jmahp.v2.23513"},{"key":"cit0042","unstructured":"2019 [cited 2020 May 29]. Available from: https:\/\/www.reuters.com\/article\/us-novartis-genetherapy-death\/second-death-in-novartis-gene-therapy-trials-under-investigation-idUSKCN1RW005"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-019-0110-7"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2020.1772747","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T03:34:39Z","timestamp":1722915279000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2020.1772747"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,11]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7,2]]}},"alternative-id":["10.1080\/14712598.2020.1772747"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2020.1772747","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,11]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-02-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}